Phoenix Health Services LLC

phxhealthohio.com

Phoenix Health Services, a small family owned and operated healthcare company, operates two skilled nursing facilities in Northeast Ohio. Sunrise Pointe Nursing & Rehab in Maple Heights and Windsong Nursing & Rehab in Akron. Check out our website to learn more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

news image

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More

Cell and Gene Therapy, AI

BENEVOLENTAI PROGRESSES BEN-34712 FOR THE POTENTIAL TREATMENT OF ALS INTO IND-ENABLING STUDIES

Businesswire | June 05, 2023

news image

BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has bee...

Read More

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

news image

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

BioSpace | March 27, 2020

news image

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More
news image

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More
news image

Cell and Gene Therapy, AI

BENEVOLENTAI PROGRESSES BEN-34712 FOR THE POTENTIAL TREATMENT OF ALS INTO IND-ENABLING STUDIES

Businesswire | June 05, 2023

BenevolentAI, a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712. BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies. Impaired retinoic acid signalling has bee...

Read More
news image

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More
news image

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

BioSpace | March 27, 2020

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

Whitepaper

resource image

Industry Outlook

A Playbook for Emerging Biotechs

Whitepaper

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

Whitepaper

resource image

Industry Outlook

A Playbook for Emerging Biotechs

Whitepaper

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us